




Ischemic stroke can be associated with varying degrees of neuronal damage and death.  To 
help combat the negative impact of cerebral ischemic events, research has turned its 
attention to the delivery of plasmids coding for key growth factors to improve neuronal 
survival.  Delivery through the blood brain barrier, however, complicates drug delivery.  
The use of antibodies presents a unique opportunity to selectively target key receptors on 
the brain and gain access to this highly selective organ.  In this study, a stable formulation 
for an antibody-conjugated polyplex system was established using polyethylene glycol-
polyethylenimine copolymers complexed with plasmid DNA.  These polyplexes offer the 
ability to deliver plasmid DNA through a self-assembling delivery system that has 
decreased clearance and selective localization to the brain.  In establishing a foundation for 
such polyplexes, this study hopes to demonstrate the utility of this system in drug delivery 


















Ischemic stroke is a serious and debilitating condition that is a leading cause of death in 
the United States. Although the extent of damage can vary, studies have shown that post-
cerebral ischemic event, there is an increase in activity in the ischemic area starting minutes 
after the incident.  Part of this increased activity is related to growth factors, which play a 
role in angiogenesis, neurogenesis and neuroplasticity.1  Brain derived neurotrophic factor 
(BDNF) is a growth factor that plays a role in both neuronal and synaptic development and 
survival.  It is known that BDNF is a part of the natural pathophysiology that occurs post-
ischemic event, however, the naturally expressed levels of BDNF are not enough to fully 
combat the damage of ischemia.2  Thus, a theory has originated that the supplementation 
of BDNF to the brain can aid in the recovery process after a cerebral ischemic event.1,2 A 
study by Schäbitz et al. (2007) showed that animals treated within five days of induced 
ischemic stroke with intravenous bolus doses of BDNF versus vehicle alone had improved 
functional recovery.3 Despite the potential benefits of BDNF supplementation, a major 
concern for its use in cerebral ischemia is successful delivery to the brain. 
Delivery of drugs through the blood brain barrier (BBB) is a significant limitation to 
pharmacological innovations that seek to implement treatments such as BDNF. While it is 
possible to deliver drug directly into the brain, this method is highly invasive and associated 
with increased risk for unwanted complications.  The intravenous route is preferred, but 
delivery across the BBB is complicated by tight extracellular junctions, low pinocytic 
activity, extensive efflux mechanisms and enzymatic activity.4  Although it is possible that 
the BBB may become leaky in areas of cerebral damage, depending on this mechanism of 
delivery alone is not reliable.  A potential method for delivery across the BBB is the 
utilization of receptor-mediated transport or transcytosis.  Delivery through this system can 
be further improved by using a polymer drug carrier. Limiting carrier size to 100 nm or 
smaller as well as polymer PEGylation can improve stability and help minimize drug 
carrier clearance through the reticuloendothelial system.4  Zhang et al. (2003) showed that 
a specific receptor could be successfully targeted using a PEGylated liposomal system 
carrying plasmid DNA using a monoclonal antibody for guided localization to the target 
receptor.5  While antibodies offer the advantage of selective binding, Yu et al. (2011) 
looked at the relationship between antibody binding affinity and the extent of uptake into 
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the brain. After comparing high- to low-affinity anti-transferrin receptor antibodies at trace 
and therapeutic doses, they found an inverse relationship between antibody affinity and 
uptake.  While high-affinity antibodies were shown to bind to the target receptor well, they 
had a low rate of release into the brain after receptor-mediated transcytosis.  The low-
affinity antibodies, however, if pushed by a concentration gradient, both bound to the target 
receptor and dissociated after transcytosis.6 Given this information, the goal of this study 
was to establish a stable formulation for an antibody-conjugated polyplex system 
composed of polyethylene glycol-polyethylenimine (PEG-PEI) copolymers complexed 
with plasmid DNA.  
 
Materials and Methods 
Materials 
Branched polyethylenimine (PEI, average MW 25 kDa), Anti-goat IgG (Fc specific) 
antibody produced in rabbit (2.12 mg/mL) and Anti-human IgG (γ-chain specific)-gold 
antibody produced in goat (5 nm colloidal gold, 171 µg/mL) were purchased from Sigma–
Aldrich (St. Louis, MO, USA).  Maleimide-polyethylene glycol-succinimidyl carboxyl 
methyl ester (MAL-PEG-SCM, average MW 5 kDa) was purchased from Creative 
PEGWorks (Chapel Hill, NC, USA).  2,4,6-trinitrobenzenesulfonate solution (TNBS, 5 % 
w/v), N-succinimidyl S-acetylthioacetate (SATA, MW 231), NAP-5 Columns (1.5 mL 
sample volume), Ellman’s reagent (MW 396), Cysteine HCl (MW 175), and Micro BCA™ 
Protein Assay Kit were obtained from ThermoFisher Scientific (Hanover Park, IL, USA).  
4–20 % Criterion™ TGX™ Gel (18 well, 30 µl each), Precision Plus Protein™ All Blue 
Prestained Protein Standards and Bio-Safe™ Coomassie Stain were purchased from Bio-
Rad (Hercules, CA, USA).  Folded Capillary Zeta Cells were obtained from Malvern 
Instruments (Malvern WR14 1XZ, UK).  Absorbance assays were done using Softmax Pro 
software.  All other materials were existing property of the Kabanov Lab (Chapel Hill, NC, 
USA). 




Synthesis of PEG-PEI Conjugate 
The preparation technique for the PEG-PEI conjugate was adapted from Zhang et al. 
(2010).  All solutions were prepared in 100 mM HEPES, pH 7.4.  A 3.6 mg/mL solution 
of branched PEI was prepared; half of the PEI solution was mixed in equal portions with a 
15 mg/mL solution of MAL-PEG-SCM.  The remaining PEI solution was used as a control.  
The PEG-PEI solution was dialyzed through a 25 kDa dialysis membrane against two 3 
hour rounds of 100 mM HEPES, pH 7.4, followed by two 3 hour rounds of deionized water 
(DI water) after it had incubated at room temperature (r.t.) for 2.5 hours.7 
TNBS Assay 
TNBS assay was used to determine free amino groups content.  A 15 mg/mL solution of 
TNBS was prepared using 5 % w/v TNBS solution and DI water.  Two samples were 
analyzed: the PEI control solution (1.8 mg/mL) and the resultant PEG-PEI conjugate. 
Using a 96 well plate, 4 µL of TNBS solution was added to 1 µL, 2 µL, and 5 µL of each 
sample, with 3 replicas each. Borate buffer, pH 9.3, was the reaction buffer; enough borate 
buffer was added to each well to bring all wells to the same final volume.  Borate buffer, 
pH 9.3, alone and this buffer with 4 µL of TNBS solution, each with 3 replicas, served as 
the assay controls.  The covered 96 well plate was allowed to incubate at r.t. for 40 minutes.  
The absorbance was measured at 420 nm. 
NMR 
The structure of PEI and the PEG-PEI conjugate was analyzed by NMR.  A sample of the 
PEI solution (1.8 mg/mL) and the PEG-PEI solution was lyophilized.  The lyophilized 
powders were then each dissolved in enough deuterium oxide (D2O) to create 700 µL of 
solution for each sample. 
Ethidium Bromide (Et-Br) Exclusion Assay 
An Et-Br exclusion assay was used to determine the concentration of PEI and PEG-PEI 
polymer needed to cause complete condensation, or compaction, of cow thalamus (ct)-
DNA.  A 0.5 mg/mL solution of PEI and of PEG-PEI was prepared; the concentration was 
based on amine content.  A 20 µg/mL solution of ct-DNA was prepared using 10 mM 
HEPES buffer, pH 7.4.  The ct-DNA solution was allowed to stand at r.t. for 10 minutes. 
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Enough Et-Br was added to the DNA solution to achieve a final Et-Br concentration of       
1 µg/mL. Half of the DNA solution was transferred to a plastic UV cuvette and using a 
fluorimeter with appropriate filters (540 nm for excitation and 590 nm for emission), the 
PEI solution was slowly added to the DNA solution in the cuvette. After each addition, the 
relative fluorescence units, or RFUs, were recorded.  This process was repeated for PEG-
PEI using the other half of the DNA solution in a new UV cuvette.  The RFU data was used 
to determine the molar ratio of polymer amines to DNA phosphates (N/P ratio) needed to 
produce stable polyplexes.  The collected data was validated by a second experiment 
completed in the same fashion with luciferase DNA. 
Agarose Gel Electrophoresis  
Agarose gel electrophoresis was used to determine the stability of polyplexes prepared 
using N/P ratios above and below the determined N/P ratio for successful condensation of 
plasmid DNA.  Enough tris base, borate, and ethylenediaminetetraacetic acid (EDTA) were 
combined in DI water to create a 10X TBE buffer.  This buffer solution was used to create 
all other TBE buffers used.  A 0.8 % agarose gel solution was prepared using agarose 
powder and 1X TBE buffer.  Prior to pouring the solution into a gel cast, enough Et-Br was 
added to the solution to produce a final Et-Br concentration of 0.5 µg/mL.  The gel was 
allowed to solidify for 1 hour.  Eleven samples were prepared for electrophoresis; each had 
20 µg/mL of ct-DNA and the same total volume (20 µL).  For both PEI and PEG-PEI, 
polyplexes were created with a N/P ratio of 0.5, 1, 1.7, 3 and 5. Additionally, a DNA control 
and a ladder were prepared; the ladder contained 6X DNA loading dye with DNA ladder.  
All samples were prepared in 10 mM HEPES, pH 7.4. Once the samples were loaded, the 
gel cast was filled with 0.5X TBE buffer. The agarose gel was allowed to run for 1 hour at 
120 V and 60 mA. After electrophoresis was complete, the gel was imaged under UV light 
to identify ct-DNA migration. 
Particle Size and Zeta Potential Characterization 
Using a Malvern Zetasizer Nano machine, dynamic light scattering (DLS) was used to 
determine polyplex size and zeta potential at different N/P ratios.  All samples were 
prepared in 10 mM HEPES, pH 7.4.  The 7 samples prepared included ct-DNA alone, and 
for both PEI and PEG-PEI, polyplex samples with a N/P ratio of 0.5, 1.7 and 5.  Samples 
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were filtered through a 200 nm pore size filter prior to their transfer to a folded capillary 
zeta cell for analysis. 
Sulfhydryl Modification of IgG Antibody and Coupling to PEG-PEI Polyplexes 
SATA was used to introduce sulfhydryl groups onto IgG antibody for subsequent antibody 
reaction with the PEG-PEI maleimide.  The protocol for IgG modification with SATA was 
based on the manufacturer’s product instructions.  This process was first performed and 
verified using polyplexes of ct-DNA; luciferase DNA was chosen as a model plasmid for 
further application.  Phosphate-buffered saline (PBS), pH 7.2-7.5, was prepared as the 
reaction buffer.  Enough SATA was dissolved in dimethyl sulfoxide (DMSO) to produce 
a 25:1 molar ratio of SATA: IgG; 2 mg of IgG were combined with SATA.  The solution 
was allowed to incubate at r.t. for 1 hour.  After incubation, the solution was purified using 
a NAP-5 column.  The column was washed with PBS and the produced acylated antibody 
was collected in PBS.  Ellman’s assay was used to ensure successful acetylation of 
sulfhydryl groups.  The protocol for assay of sulfhydryl groups with Ellman’s reagent was 
based on the manufacturer’s instructions using cysteine standards and a reaction buffer of 
0.1 M sodium phosphate with 1 mM EDTA.  The acylated antibody was then deacetylated 
to generate free sulfhydryl groups per the manufacturer’s instructions using 0.5 M 
hydroxylamine with 25 mM EDTA in PBS, pH 7.2-7.5, as the deacetylation solution and 
a NAP-5 column.  Deacetylated IgG was then mixed with 1 mL of PEG-PEI polyplexes, 
prepared in 10 mM HEPES, pH 7, using luciferase DNA at a N/P ratio of 10.  The pH of 
the mixture was adjusted to a pH of 7.0 and the mixture was allowed to incubate at r.t. for 
12 hours.  Agarose gel electrophoresis was performed using the method outlined earlier to 
compare the stability of unmodified luciferase DNA containing PEG-PEI polyplexes to the 
generated IgG modified luciferase DNA containing PEG-PEI polyplexes.   
Transmission Electron Microscopy (TEM) 
TEM imaging was performed to characterize differences in binding affinity, size and shape 
between IgG modified PEG-PEI polyplexes and unmodified PEG-PEI polyplexes.  
Binding affinity was determined by the extent of gold particle aggregation visualized when 
each polyplex sample was exposed to anti-human IgG containing 5 nm gold particles.  Each 
polyplex sample was combined with IgG containing gold in a 1:1.71 ratio, respectively.  
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Imaging was accomplished through equipment provided by the Chapel Hill Analytical and 
Nanofabrication Laboratory, Chapel Hill, NC.  
MicroBCA Protein Assay with IgG Standards 
MicroBCA was performed as outlined in the manufacturer’s instructions using a 96 well 
plate with the exception that anti-goat IgG standards were used instead of albumin 
standards; the standards’ concentrations were as outlined per manufacturer despite use of 
anti-goat IgG.  The 96 well plate was incubated at 37 °C for two hours; the final 
concentration was based on measured absorbance at 562 nm. 
Denaturing Gel Electrophoresis 
SDS-polyacrylamide gel electrophoresis (SDS-PAGE) was utilized to confirm the 
presence of PEI, PEG-PEI and IgG in each sample through gel migration.  The following 
11 samples were prepared: 3 µg samples of IgG, ct-DNA, and luciferase DNA; 5 µg 
samples of free PEI, free PEG-PEI, unmodified ct-DNA PEI polyplexes, unmodified ct-
DNA PEG-PEI polyplexes, IgG modified ct-DNA PEG-PEI polyplexes, unmodified 
luciferase DNA PEI polyplexes, unmodified luciferase DNA PEG-PEI polyplexes and IgG 
modified luciferase DNA PEG-PEI polyplexes.  Each sample was heated at 100 °C for 10 
minutes.  An electrophoresis tank with a 4–20 % Criterion Gel was filled with running 
buffer, 1X tris/glycine, which was prepared from 10X tris/glycine solution and DI water.  
Twenty microliters of each sample were loaded into the gel.  Ten microliters of all blue 
standard were added as the ladder.  The electrophoresis tank was allowed to run for 2 hours 
at 100 V and 50 mA.  The finished gel was stained with coomassie for 1 hour on a rocker, 
washed with DI water three times and imaged. 
 
Results and Discussion 
PEG-PEI Conjugate 
Utilizing an antibody-conjugated polyplex system allows for plasmid delivery to the brain 
through a receptor-mediated endocytosis.  While antibody targeting permits the drug 
carrier to cross the BBB, the polymers used must facilitate antibody conjugation while 
maintaining structural stability.  Branched PEI is a cationic polymer that can spontaneously 
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form polyion complex with the negatively charged phosphate backbone of plasmid DNA 
through electrostatic interactions.  The positive charge, however, is limiting in terms of 
distribution out of the vasculature.  The addition of nonionic maleimide PEG offers 
enhanced water-solubility and a “handle” for antibody modification.  The reactive group 
on MAL-PEG-SCM, succinimidyl carboxyl methyl ester, reacts with a primary amine on 
the branched PEI to form an amide bond that links the two polymers.8  A general schematic 
for this reaction is shown in Figure 1. 
TNBS Assay 
Structurally, PEI has several available amines per branched segment that could be targeted 
by SCM in the conjugation reaction. It has been shown, however, that roughly one-third of 
these amines are not available for conjugation.9  For PEI with a molecular weight of 25,000 
Da, it was assumed that each repeating unit of PEI is 43 g/mol and contains one amine.  





Figure 1. PEG-PEI Conjugation Reaction Scheme.  The SCM ester on MAL-PEG-SCM reacts 
with a primary amine on the PEI molecule to form an amide bond.  The resulting PEG-PEI 
conjugate has an available maleimide group for further coupling reactions. 
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available for conjugation. TNBS assay was performed to determine the amine content of 
the generated conjugate in comparison to a PEI control.  TNBS was believed to be titrating 
the remaining amines and producing a signal that corresponded to the concentration of PEI 
in the samples.  If less than 10% of the amines were being modified, then any loss in signal 
above the modification extent would have been attributed not to the modification of PEI 
by PEG, but to the discrepancy in the concentration of the overall PEI.  The absorbance 
data plotted in Figure 2 shows about a 50 % reduction in absorbance between the PEI and 
PEG-PEI samples.  This change, therefore, likely does not represent the extent of 
modification; the preparation technique used for the conjugate produced a PEG to PEI feed 
ratio of 20.83, which under ideal conditions would theoretically correspond to 5.15 % 
modification.  Given intrinsic experimental error, this relatively low modification rate 
would present a challenge in determining amine content.  Additionally, it is important to 
consider that to produce a purified PEG-PEI sample, the PEG-PEI solution was dialyzed, 
as described earlier.  The collected data, given the expected modification rate, showed that 
the dialysis resulted in enough of a PEG-PEI concentration change that it was unclear how  
Figure 2. TNBS Assay Absorbance Data.  Prior to dialysis of PEG-PEI, the PEI control and 
PEG-PEI solutions each contained 1.8 mg/mL of PEI.  Equal volumes of PEI and PEG-PEI 
were reacted with TNBS buffer.  The measured absorbance corresponded to the concentration 
of amine.  Thus, the molar content of PEI was determined for each sample.  The loss of signal 
was attributed to differences in the overall PEI concentration.  Based on the lost PEI content, 




much of the change in absorbance was due to dilution versus modification.  Distinguishing 
between these two influences would have required further measurement of the total amine 
content by an independent method such as an elemental analysis, which was not performed 
in this study.  Based on the data obtained, it was calculated that there were roughly four 
PEG per PEI molecule.  Considering the expected amine content in each sample and the 
fact that one PEG conjugates to a single amine, this would translate to roughly 1 % 
modification, an extent of modification that TNBS is not sensitive enough to measure.  
TNBS assay measures the difference in modifiable groups, but to use this assay the starting 
amine content must be known.  The belief that the dilutional effects of dialysis could be 
overcome by using a known concentration of PEI did not hold true in this experiment.  
Thus, it was found that TNBS assay was not a good technique for amine determination and 
NMR was needed to show successful modification.  
NMR 
NMR spectroscopy was performed to compare the structural differences between PEI and  
PEG-PEI.  The spectrum of the buffer solution, 100 mM HEPES, in which these polymers 
were prepared was also obtained.  Based on previous studies, it was expected that the peaks 
associated with PEI would be around 2.40-2.75 ppm for PEI10 and roughly 2.00-2.60 ppm 
and 3.20-3.60 ppm for PEI and PEG, respectively, when conjugated.11 As shown in Figure 
3, the PEI spectrum contained a peak around 2.65-2.80 ppm, which would be an 
appropriate position for a PEI peak.  While this area overlapped with a HEPES peak, the 
PEI and HEPES spectra showed that this peak was shifted in its position and differed in 
shape from that of HEPES; this supported the inference that this peak was associated with 
PEI.  This was further confirmed in the PEG-PEI spectrum, which showed a similar 
overlapping in roughly the same area.  The presence of a distinct peak around 3.51-3.61 
ppm was believed to be due to the presence of PEG in the solution.  Despite these 
conclusions, the overlapping HEPES peaks complicate interpretation of this data.  A 
potential limitation was the presence of the HEPES peaks; only the PEG-PEI underwent 
dialysis and no further dialysis occurred prior to imaging.  Future experiments would 
benefit from performing dialysis for both NMR samples prior to imaging.  For the purposes 








Et-Br Exclusion Assay 
Complete condensation of plasmid DNA by the carrier polymer is key to creating stable 
polyplexes that could successfully deliver the intended payload to the brain.  Et-Br is an 
intercalating agent that is able to produce a fluorescent signal upon binding to plasmid 
DNA.  This fluorescence is diminished in the presence of cationic species, such as PEI, 
which can displace the Et-Bt on the DNA.  In measuring this change in fluorescence, it is 
possible to determine the molar ratio of polymer amines to DNA phosphates (N/P ratio) 
that results in full condensation of plasmid DNA.12  A plateau in fluorescence denotes the 
equivalence point or the point at which full condensation has occurred.  Et-Br exclusion 
assay was performed with both the PEI and PEG-PEI polymers.  The ideal N/P ratio would 
be one that allowed for full condensation with both polymers.  The expected amine  
Figure 3. NMR Spectrums for PEI (top left 
corner), PEG-PEI (top right corner) and 100 
mM HEPES (left).  All three spectra show three 
peaks which can be associated with the HEPES 
buffer used in the polymers’ preparation.  These 
peaks are slightly shifted from their original 
position at roughly 2.55-2.95 ppm, 2.95-3.05 
ppm and 3.65-3.72 ppm in the PEI and PEG-PEI 
spectra.  The PEI spectrum contains a peak 
around 2.65-2.80 ppm that was associated with 
overlapping HEPES and PEI peaks.  A similar 
overlapping peak was seen in the PEG-PEI 
spectrum, along with a distinct PEG peak at 









content of each polymer and the volume of polymer added at each absorbance reading was 
used to calculate the N/P ratio.  The equivalence point for PEG-PEI occurred after fewer 
additions of polymer in comparison to PEI, which was likely due to the stability offered by 
the neutral charge and steric contributions of PEG.  Based on the data shown in Figure 4, 
it was determined that a N/P ratio of 1.7 would be sufficient to produce condensation in 
both polymers. 
Agarose Gel Electrophoresis  
Agarose gel electrophoresis allows for the visualization of plasmid DNA migration.  At 
N/P ratios above the equivalence point, polyplexes should be stable and maintain plasmid 
DNA condensation.  Below the equivalence point, free plasmid DNA is available and 
would be expected to migrate down the gel due to electrostatic attraction to the positively 
charged bottom of the electrophoresis tank.  The absence of DNA migration indicates 
stable polyplex formation.  Although the equivalence point for PEI was at a N/P ratio of 
1.65, no ct-DNA migration was seen at a N/P ratio of 1 and higher.  This may be attributed 
to the attractive forces between DNA phosphates and PEI amines, which may be enough 
at a N/P ratio of 1 to hold the plasmid DNA close to the PEI even without full condensation.  
The signal visible at the well for PEI ct-DNA polyplexes with N/P ratios of 1.7 and higher  
Figure 4. Graph of RFU Data Versus Calculated N/P Ratios.  The plotted data shows the 
loss of fluorescence associated with each addition of polymer (0.5 mg/mL) to ct-DNA solution 
(20 µg/mL), which is represented as a N/P ratio.  The point at which the loss of fluorescence 
plateaus is the equivalence point.  This was shown to have occurred at roughly a N/P ratio of 



















was due to the presence of plasmid DNA in the polyplex.  Since complex formation is 
based on electrostatic interactions, the polymers are not locked into place.  The attraction 
of PEI to the negatively charged top of the electrophoresis tank, along with the polymer’s 
motion, allows for plasmid DNA to produce a slight signal despite condensation.  For PEG-
PEI, although the equivalence point was determined to be at 0.69, polyplex stability was 
shown at a higher N/P ratio.  This may imply that while a smaller number of PEG-PEI is 
needed for condensation, in the presence of an interacting force, such as the charge applied 
by the electrophoresis tank, alternative attractive forces may overcome the electrostatic 
interaction between PEG-PEI and plasmid DNA.  Despite this, both polymer polyplexes 
showed stability at a N/P ratio equal to and greater than 1.7. 
Particle Size and Zeta Potential Characterization 
Dynamic light scattering (DLS) was used to characterize polyplex size and zeta potential.  
Given that PEI is a cationic polymer, PEI polyplexes were expected to have increasingly 
positive zeta potentials as the concentration of PEI increased.  With PEG-PEI, it was  
Figure 5. Agarose Gel of PEI and PEG-PEI ct-DNA Polyplexes at Variable N/P Ratios.  
Each well contains 20 µL of sample.  For PEI ct-DNA polyplexes, stability was demonstrated 
before the equivalence point.  For PEG-PEI ct-DNA polyplexes, stability was demonstrated at 
a N/P ratio slightly higher than the equivalence point.  Both polymer polyplexes showed 








expected that the PEG component would contribute to a neutral surface charge; with the 
addition of more polymer, or higher N/P ratios, it was anticipated that the surface charge 
would move from a positive to a more neutral charge.  The observed diameter for the 
measured polyplexes varied from 140 nm to 230 nm; these averages were likely skewed 
by aggregates, which were noted to be present for all samples.  This was supported by the 
moderately polydisperse distribution noted in Table 1.  Surprisingly, the overall zeta 
potential was negative.  While both PEI and PEG-PEI showed a trend toward neutrality, it 
was unclear what contributed to the observed negative charge.  Some literature indicates 
that pH may play a role in measured zeta potential, in addition to the N/P ratio used,12 but 
overall it is accepted that PEI should produce positive zeta potentials at physiological pH. 
Sulfhydryl Modification of IgG Antibody and Coupling to PEG-PEI Polyplexes 
The addition of monoclonal antibodies to a polyplex system allows for receptor-mediated 
transport, but successful antibody targeting depends on an antibody modification process 
that retains antigen-binding activity.  SATA modification of antibodies aids in the addition 
of a protected thiol group without loss of activity and offers the ability to store modified 
antibodies for prolonged periods of time.8  The SATA modification chemistry is shown in 
Figure 6.  Antibody thiolation generates a reactive group for conjugation with the PEG-
PEI maleimide.  Prior to deacetylation of the SATA modified antibodies, an Ellman’s assay 
was performed to identify any free or unprotected sulfhydryl groups. 
Table 1. Size and Zeta Potential Data for PEI and PEG-PEI Polyplexes at Variable N/P 
Ratios.  The average diameter of the polyplexes increased for PEI and decreased for PEG-PEI 
with higher N/P ratios.  Overall, the zeta potential for PEI was negative rather than positive, but 
with increasing N/P ratios, the surface charge trended toward neutrality.  The same was 








Ellman’s reagent reacts with free sulfhydryl groups to form disulfide bonds and a reduced 
product that can be measured at 412 nm.14  Any absorbance data generated from the assay 
should correlate to unprotected sulfhydryl groups. The calculated sulfhydryl concentration 
was 0.0614 nmol.  This was deemed acceptable considering that some of the natural 
disulfide groups in the antibody may have contributed to the signal.  After deacetylation, 
the thiolated antibody was combined with luciferase DNA containing polyplexes with a 
N/P ratio of 10 to produce IgG coated PEG-PEI polyplexes.  The scheme for this reaction 
is shown in Figure 7.  This process was performed with both ct-DNA and luciferase plasmid 
DNA, but the luciferase plasmid DNA was shown to have more consistent behavior.  
Agarose gel electrophoresis showed that both unmodified luciferase DNA containing PEG-
PEI polyplexes and IgG modified luciferase DNA containing PEG-PEI polyplexes, both 
with a N/P of 10, retained their stability despite the described manipulation. 
Transmission Electron Microscopy 
Polyplex modification with IgG was expected to generate polyplexes with a different size 
and binding affinity when compared to unmodified polyplexes.  The extent of gold particle  
Figure 6. Protein Modification with SATA Reaction Scheme.  SATA, containing a protected 
sulfhydryl group, reacts with the primary amines of the target protein to form an amide bond. 
The SATA-modified protein is then deacetylated with hydroxylamine to produce a free 


















aggregation observed after combining polyplexes with anti-human IgG containing 5 nm 
gold particles was used as a surrogate to predicted target receptor binding affinity.  The 
resultant TEM images can be seen in Figure 8.  The gold particles in the anti-human IgG 
were in colloid form; imaging of this sample alone was completed to visualize gold particle 
and colloid distribution.  TEM imaging of the anti-human IgG showed gold particles with 
a random distribution and colloids of up to 200 nm in diameter.  The presence of colloid 
was seen in both the modified and unmodified polyplex images.  For unmodified PEG-PEI 
polyplexes, random distribution of gold particles was seen in the background.  Some gold 
particle aggregation was observed with unmodified polyplexes, but this was likely due to 
the mild affinity of the gold containing colloids to the PEG-PEI of the unmodified 
polyplexes.  In comparison, the greater extent of gold particle aggregation at the IgG 
modified polyplexes, along with fewer background gold particles, indicated that the 
modified polyplexes demonstrated a greater affinity than the unmodified polyplexes.  This 
was correlated to the presence of IgG in the modified samples.  However, the observed 
aggregation was not consistent throughout the sample signifying that the degree of 
modification was not consistent from one polyplex to the next. The modified and 
unmodified polyplexes both appeared to be up to roughly 0.5 µm in diameter.  Closer  
Figure 7. PEG-PEI Polyplex Modification with Sulfhydryl IgG Reaction Scheme.  The 
generated sulfhydryl on IgG reacts with the maleimide of the PEG-PEI polyplex to form a 




analysis of the images showed that these polyplexes had been flattened out, possibly in the 
grid drying process, and were likely smaller than this in diameter when in their natural 
spherical or ovular shape.  Based on these images, it was accepted that there was successful 
modification of polyplexes with IgG and that this IgG demonstrated a greater binding 
affinity than unmodified PEG-PEI polyplexes. 
MicroBCA Protein Assay with IgG Standards 
MicroBCA protein assay using anti-goat IgG standards was performed for modified and 
unmodified polyplexes.  Previous versions of this experiment showed that using albumin 
standards resulted in absorbance data that included a signal from alternative protein sources 
other than IgG.  Using IgG standards was believed to produce a more accurate measure of 
antibody concentration.  The resultant IgG concentration in the modified polyplex sample 
was found to be 1.028 mg/mL.  Given this value, the expected total concentration of IgG  
 
 
Figure 8. TEM Images of Anti-human IgG 
Containing 5 nm Gold Particles (top left corner), 
Unmodified PEG-PEI Polyplexes (top right 
corner) and IgG Modified PEG-PEI Polyplexes 
(left).  The image of anti-human IgG containing 5 
nm gold particles served as the control to 
demonstrate gold particle and colloid distribution. 
A random distribution of gold particles was seen in 
the control image. Both the modified and 
unmodified polyplex images showed background 
colloids. Some colloid and gold affinity was seen 
with unmodified polyplexes, but not to the extent 








would exceed the amount used to generate the modified PEG-PEI polyplexes, which was 
2 mg.  Therefore, this finding supported the belief that IgG modification was not consistent 
throughout the modified sample.   
Denaturing Gel Electrophoresis 
SDS-PAGE is an electrophoresis technique that can be used to visualize the migration 
patterns of denatured samples.  By providing a comparison of variable samples, SDS-
PAGE presented a method for identifying the presence of PEI, PEG-PEI and IgG in each 
sample.  The imaged gel can be seen in Figure 9.  As expected with unmodified PEI 
polyplexes, a band was seen at the well marking the presence of PEI which is drawn to the 
negatively charged top of the electrophoresis tank and does not migrate down the gel.  In 
comparison, the unmodified PEG-PEI polyplexes only showed a faint band at the well and 
Figure 9. Denaturing Gel Comparison of Polymers and Polyplexes.  The free samples 
corresponded to the plasmid DNA and polymer controls, while the modified and unmodified 
samples corresponded to the polyplexes.  The migration pattern associated with each denatured 
sample revealed the varying components.  Looking across the lanes, it is possible to see the 
presence of PEI, PEG-PEI and/or IgG in the samples.   




had an additional segment indicating the presence of PEG.  While some PEI may have 
broken apart from the PEG-PEI in the heating process to contribute to the band at the well, 
the weakened signal along with the additional smear confirmed the presence of the PEG-
PEI conjugate.  This same PEG-PEI smear was seen in the modified polyplex samples, but 
these sample also demonstrated a band in the region of IgG, indicating the presence of 
PEG-PEI conjugate and IgG.  Given these observations, it was accepted that successful 
PEG-PEI conjugation and IgG modification were achieved in this study. 
Closing Remarks 
The goal of this study was to demonstrate that a stable formulation of an antibody-
conjugated polyplex system composed of PEG-PEI copolymers complexed with plasmid 
DNA could be generated and that this system could have future utility for plasmid delivery 
to the brain.  Through the experiments described in this paper, sufficient data has been 
generated in support of this goal.  Future applications should seek to optimize the 
techniques described.  Additionally, in vitro models examining the ability of these modified 
polyplexes to deliver a payload through a human endothelium would be needed to 
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